Skip to main content
. Author manuscript; available in PMC: 2021 Sep 15.
Published in final edited form as: Cancer Res. 2021 Jan 26;81(6):1500–1512. doi: 10.1158/0008-5472.CAN-20-0832

Figure 1. lncTCL6 is a downregulated and miR-155 is upregulated in RCC and lncTCL6 is direct target of miR-155.

Figure 1.

(A) Expression levels of TCL6 in KIRC-TCGA cohort (normal =72 and tumor = 518), p value calculated by Mann-Whitney test. (B) Relative TCL6 expression in ccRCC tissue and matched adjacent normal regions as assessed by qRT-PCR (SFVAMC cohort, n=67), p value calculated by Mann-Whitney test. (C) Relative expression levels of TCL6 in Caki-1, 786-O compared to normal non-malignant renal cell line HK2 (N=3). (D) Expression levels of miR-155 in the KIRC-TCGA cohort (normal =71 and tumor = 544), p value calculated by Mann-Whitney test. (E) Relative miR-155 expression in ccRCC tissue and matched adjacent normal regions as assessed by qRT-PCR (SFVAMC cohort, n=83), p value calculated by Mann-Whitney test. (F) Relative expression levels of miR-155 in Caki-1, 786-O compared to normal non-malignant renal cell line HK2 (N=3) (G) Correlation of miR-155 expression with lncTCL6 expression in patients from TCGA cohort. p-value calculated using the Spearman test of correlation. (H) Complimentary binding sites for miR-155 in TCL6 gene. (I) and (J) Luciferase assays showing decreased reporter activity after co-transfection of either wild-type target sequence compared with mutant target site (control) with miR-155 in Caki-1 and 786-O cells (N=3).